ID: MRFR/HC/6963-CR | October 2019 | Region: Global | 78 pages
Metabolomics Services Market is anticipated to record a CAGR of 7.77% to accomplish USD 16,291.0 Million by the end of 2025. Metabolomics can be described as examining and analyzing biochemical processes relating to intermediates and byproducts of metabolic activities. These products are known as metabolomes, which reproduce all metabolites involved in numerous reactions in an organism, counting secondary metabolites, signaling molecules, hormones, and metabolic intermediates. Its application in toxicology, environmental analysis, disease research, agriculture, biofuel development & nutrition is estimated to be a broad scope for developing the metabolomics services market size in the coming period.
The cold chain and pharmaceutical industries were impelled to revolutionize throughout vaccine development, including the production of temperature-controlled packages that met the revised deep-frozen vaccine storage requirements and amplified demand for existing products. The industry soared to the challenge posed by COVID, working by employing unique ways to bolster the metabolomics services market share. The metabolome is exceptionally dynamic, and metabolism shifts often lead to clinical phenotype changes. The use of metabolomics is being leveraged to shape our understanding of COVID-19, which could play a vital role. The fruitful cases for biomarker study in pneumonia, sepsis, and comorbidities related to many COVID-19 infections indicate the possibility of metabolomics to bring about an adapted health care strategy for Covid-19, delivering safe and effective treatments to patients.
Growing Prevalence Of Cancer
The surge in cancer cases globally in different body areas is predicted to motivate the metabolomics services market size in the upcoming period.
Technological Advancements In Instrumentation
The breakthroughs in the instruments used for metabolomics related studies is estimated to enhance the global market considerably in the forecast period.
Increasing Application Of Metabolomics
The use of metabolomics in various studies for diverse ailments is predicted to spur the growth of the metabolomics market.
Expansion In Developing Countries
The development of emerging economies is estimated to shape the metabolomics market considerably in the forecast period. With increased funding for businesses' research and growth, it is predicted to transform the countries' metabolomics market.
High Cost Of Instruments
The raised costs associated with using the metabolomics tools and services are estimated to stagnate the growth of the metabolomics market.
Government Policies And Regulations
The strict regulations related to healthcare-related businesses are estimated to create fresh expansion opportunities in the forecast period.
By Product And Service
The mass spectrometry segment is estimated to have a majority share of the global market, with metabolomics bioinformatics services coming in second through the forecast period.
The biomedical & pharmaceutical segment accounted for the largest market share in 2018 and is estimated to control the upcoming period's global market share.
Americas Regional Market To Lead With Vast Expertise
The Americas regional market is expected to hold the market's principal share. This is due to the swelling patient population base that is suffering from cancer, and cardiovascular diseases are predicted to boost the metabolomics market growth in this region.
Presence Of Strong Contenders To Spur European Region
The European market holds the next major position in the global metabolomics services market. Numerous companies in the region provide metabolomics services, which is predicted to drive the region's growth in the global metabolomics services market.
APAC To Be Incentivized By Huge Patient Base
The Asia Pacific regional metabolomics market is estimated to be the fastest mounting region due to many patient populations suffering from chronic disease and collective demand for therapy.
The prolific companies in the Metabolomics Market are
Jan 2021 OWL and BIOSFER, biotech players, have arrived at a strategic partnership to reinforce R&D in developing diagnostic methods and personalized medicine use metabolomics. The agreement permits both groups to identify prospects, produce detailed proposals, and find the most suitable backing to safeguard these projects' victory and make them advantageous for society and the biotechnology industry. OWL and BIOSFER have widespread knowledge of metabolomic technology for application in various areas, such as increasing new biomarkers to create diagnostic products or encourage advanced platforms for studies and clinical tests in the pharmaceutical industry.
Jan 2021 numares A.G., a leading metabolomics diagnostics company, and Bruker Corporation have decided to cooperate to bring novel diagnostics tests employing NMR to the laboratory market unmet medical requirements. The tests are created on the automated measurement of metabolites via artificial intelligence and a strong magnetic field. The platform is advertised under the numares brand AXINON. This partnership will support the current transition of AXINON platform from research into routine clinical use and makes it accessible to all patients as a reasonably priced, day-to-day diagnostic standard.
Aug 2020 Metabolon, Inc., the global leader in metabolomics, has entered into a multi-year association with Merck KGaA, Germany, a top science and technology company. Merck KGaA, Germany, runs its biopharmaceuticals business in the U.S. and Canada as EMD Serono. Metabolon will back clinical & translational research developments through therapeutic areas as an exploratory metabolomics associate. Through this partnership, Metabolon will achieve worldwide metabolomics and deliver top biological interpretation and examination of the results to shed light on biomarkers and biochemical pathways detected to progress both the rapidity and yield of Merck KGaA's drug development pipeline.
July 2020 ReviveMed has announced that they are pursuing an assessment analysis with Bristol Myers Squibb. This analysis will use ReviveMed's artificial intelligence (A.I.) platform to understand the mechanisms of resistance and response to immunotherapies in cancer patients. ReviveMed has built one of the most comprehensive databanks about metabolites and their relation with other molecules. Their exclusive A.I. algorithm utilizes this database to classify a large number of metabolites for individual patients quickly and at a low cost. ReviveMed's AI-driven platform interprets this large number of data to discover novel disease mechanisms and molecules for drug discovery purposes.
By Product And Service
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Product and Service, Application, End-User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Agilent Technologies, Inc. (US), Waters (US), Bruker (US), TMIC (CANADA), Thermo Fisher Scientific (US), Biocrates Life Sciences AG (AUSTRIA), Creative Proteomics (US), Human Metabolome Technologies America Inc (JAPAN), Shimazdu Corporation (Japan), and Metabolon, INC (US)|
|Key Market Opportunities||Expansion In Developing Countries|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
The valuation of the global metabolomics services market is estimated to reach USD 16,291.0 MN. by 2025.
The global metabolomics services market is projected to grow at approximately 7.77% CAGR during the forecast period (2019-2025).
High prevalence of diseases such as cancer, neurological disorders, and cardiac diseases across the globe.
North America holds the largest share in the global metabolomics services market, followed by Europe and the Asia Pacific, respectively.
Agilent Technologies, Inc. (US), Waters (US), Bruker (US), Thermo Fisher Scientific (US), TMIC (Canada), Biocrates Life Sciences AG (Austria), Metabolon, INC (US), Creative Proteomics (US), and Human Metabolome Technologies America Inc (Japan), are some of the major players operating in the metabolomics services market.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.